Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans.
Kerob
Delphine
D
Department of Dermatology, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
Pedeutour
Florence
F
Leboeuf
Christophe
C
Verola
Olivier
O
de Kerviler
Eric
E
Servant
Jean Marie
JM
Sarandi
Farid
F
Bousquet
Guilhem
G
Madelaine-Chambrin
Isabelle
I
Pruvost
Christelle
C
Calvo
Fabien
F
Janin
Anne
A
Lebbe
Celeste
C
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D003131:Combined Modality Therapy; D020732:Cytogenetic Analysis; D018223:Dermatofibrosarcoma / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D010879:Piperazines / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D011743:Pyrimidines / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate